Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Wedge, D.C., Gundem, G., Mitchell, T., Woodcock, D.J., Martincorena, I., Ghori, M., Zamora, J., Butler, A., Whitaker, H., Kote-Jarai, Z., et al. (2018). Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat genet, Vol.50 (5), pp. 682-692.  show abstract

Rosenstein, B.S., Rao, A., Moran, J.M., Spratt, D.E., Mendonca, M.S., Al-Lazikani, B., Mayo, C.S. & Speers, C. (2018). Genomics, bio specimens, and other biological data: Current status and future directions. Med phys, Vol.45 (10), pp. e829-e833.

Antolin, A.A., Tym, J.E., Komianou, A., Collins, I., Workman, P. & Al-Lazikani, B. (2018). Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell chem biol, Vol.25 (2), pp. 194-205.e5.  show abstract

Cato, L., Neeb, A., Sharp, A., Buzón, V., Ficarro, S.B., Yang, L., Muhle-Goll, C., Kuznik, N.C., Riisnaes, R., Nava Rodrigues, D., et al. (2017). Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. Elife, Vol.6.  show abstract

Martínez-Jiménez, F., Overington, J.P., Al-Lazikani, B. & Marti-Renom, M.A. (2017). Rational design of non-resistant targeted cancer therapies. Sci rep, Vol.7, p. 46632.  show abstract

Coker, E.A., Mitsopoulos, C., Workman, P. & Al-Lazikani, B. (2017). SiGNet: A signaling network data simulator to enable signaling network inference. Plos one, Vol.12 (5), p. e0177701.  show abstract

Tym, J.E., Mitsopoulos, C., Coker, E.A., Razaz, P., Schierz, A.C., Antolin, A.A. & Al-Lazikani, B. (2016). canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic acids res, Vol.44 (D1), pp. D938-D943.  show abstract

Al-Lazikani, B. & Workman, P. (2016). Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome. Future med chem, Vol.8 (14), pp. 1711-1716.

Campbell, J., Ryan, C.J., Brough, R., Bajrami, I., Pemberton, H.N., Chong, I.Y., Costa-Cabral, S., Frankum, J., Gulati, A., Holme, H., et al. (2016). Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell rep, Vol.14 (10), pp. 2490-2501.  show abstract

Workman, P., Clarke, P.A. & Al-Lazikani, B. (2016). Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget, Vol.7 (4), pp. 3658-3661.  show abstract

Antolin, A.A., Workman, P., Mestres, J. & Al-Lazikani, B. (2016). Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Curr pharm des, Vol.22 (46), pp. 6935-6945.  show abstract

Pearl, L.H., Schierz, A.C., Ward, S.E., Al-Lazikani, B. & Pearl, F.M. (2015). Therapeutic opportunities within the DNA damage response. Nat rev cancer, Vol.15 (3), pp. 166-180.  show abstract

Mitsopoulos, C., Schierz, A.C., Workman, P. & Al-Lazikani, B. (2015). Distinctive Behaviors of Druggable Proteins in Cellular Networks. Plos comput biol, Vol.11 (12), p. e1004597.  show abstract

Bulusu, K.C., Tym, J.E., Coker, E.A., Schierz, A.C. & Al-Lazikani, B. (2014). canSAR: updated cancer research and drug discovery knowledgebase. Nucleic acids res, Vol.42 (Database issue), pp. D1040-D1047.  show abstract

Walters, Z.S., Villarejo-Balcells, B., Olmos, D., Buist, T.W., Missiaglia, E., Allen, R., Al-Lazikani, B., Garrett, M.D., Blagg, J. & Shipley, J., et al. (2014). JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene, Vol.33 (9), pp. 1148-1157.  show abstract

Al-Lazikani, B. & Workman, P. (2013). Unpicking the combination lock for mutant BRAF and RAS melanomas. Cancer discov, Vol.3 (1), pp. 14-19.  show abstract

Gonzalez de Castro, D., Clarke, P.A., Al-Lazikani, B. & Workman, P. (2013). Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin pharmacol ther, Vol.93 (3), pp. 252-259.  show abstract

Box, C., Mendiola, M., Gowan, S., Box, G.M., Valenti, M., Brandon, A.D., Al-Lazikani, B., Rogers, S.J., Wilkins, A., Harrington, K.J., et al. (2013). A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. Eur j cancer, Vol.49 (11), pp. 2512-2521.  show abstract

Workman, P., Al-Lazikani, B. & Clarke, P.A. (2013). Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr opin pharmacol, Vol.13 (4), pp. 486-496.  show abstract

Workman, P. & Al-Lazikani, B. (2013). Drugging cancer genomes. Nature reviews drug discovery, Vol.12 (12), pp. 889-890.

Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012). ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic acids res, Vol.40 (Database issue), pp. D1100-D1107.  show abstract

Halling-Brown, M.D., Bulusu, K.C., Patel, M., Tym, J.E. & Al-Lazikani, B. (2012). canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic acids res, Vol.40 (Database issue), pp. D947-D956.  show abstract

Al-Lazikani, B., Banerji, U. & Workman, P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nat biotechnol, Vol.30 (7), pp. 679-692.  show abstract

Workman, P., Clarke, P.A. & Al-Lazikani, B. (2012). Personalized medicine: patient-predictive panel power. Cancer cell, Vol.21 (4), pp. 455-458.  show abstract

Orchard, S., Al-Lazikani, B., Bryant, S., Clark, D., Calder, E., Dix, I., Engkvist, O., Forster, M., Gaulton, A., Gilson, M., et al. (2012). Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group. Nat rev drug discov, Vol.11 (9), p. 730.

Suwaki, N., Vanhecke, E., Atkins, K.M., Graf, M., Swabey, K., Huang, P., Schraml, P., Moch, H., Cassidy, A.M., Brewer, D., et al. (2011). A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci transl med, Vol.3 (85), p. 85ra47.  show abstract

Bellis, L.J., Akhtar, R., Al-Lazikani, B., Atkinson, F., Bento, A.P., Chambers, J., Davies, M., Gaulton, A., Hersey, A., Ikeda, K., et al. (2011). Collation and data-mining of literature bioactivity data for drug discovery. Biochem soc trans, Vol.39 (5), pp. 1365-1370.  show abstract

Orchard, S., Al-Lazikani, B., Bryant, S., Clark, D., Calder, E., Dix, I., Engkvist, O., Forster, M., Gaulton, A., Gilson, M., et al. (2011). Minimum information about a bioactive entity (MIABE). Nat rev drug discov, Vol.10 (9), pp. 661-669.  show abstract

Abad-Zapatero, C., Perišić, O., Wass, J., Bento, A.P., Overington, J., Al-Lazikani, B. & Johnson, M.E. (2010). Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug discov today, Vol.15 (19-20), pp. 804-811.  show abstract

Berriman, M., Haas, B.J., LoVerde, P.T., Wilson, R.A., Dillon, G.P., Cerqueira, G.C., Mashiyama, S.T., Al-Lazikani, B., Andrade, L.F., Ashton, P.D., et al. (2009). The genome of the blood fluke Schistosoma mansoni. Nature, Vol.460 (7253), pp. 352-358.  show abstract

Workman, P. (2009). Drugging the cancer genome. Drug discovery today, (July 2009).

Al-Lazikani, B., Hill, E.E. & Morea, V. (2008). Protein structure prediction. Methods mol biol, Vol.453, pp. 33-85.  show abstract

Overington, J.P., Al-Lazikani, B. & Hopkins, A.L. (2006). How many drug targets are there?. Nat rev drug discov, Vol.5 (12), pp. 993-996.  show abstract

Marks, D.J., Harbord, M.W., MacAllister, R., Rahman, F.Z., Young, J., Al-Lazikani, B., Lees, W., Novelli, M., Bloom, S. & Segal, A.W., et al. (2006). Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet, Vol.367 (9511), pp. 668-678.  show abstract

Freilich, S., Spriggs, R.V., George, R.A., Al-Lazikani, B., Swindells, M. & Thornton, J.M. (2005). The complement of enzymatic sets in different species. J mol biol, Vol.349 (4), pp. 745-763.  show abstract

George, R.A., Spriggs, R.V., Bartlett, G.J., Gutteridge, A., MacArthur, M.W., Porter, C.T., Al-Lazikani, B., Thornton, J.M. & Swindells, M.B. (2005). Effective function annotation through catalytic residue conservation. Proc natl acad sci u s a, Vol.102 (35), pp. 12299-12304.  show abstract

George, R.A., Spriggs, R.V., Thornton, J.M., Al-Lazikani, B. & Swindells, M.B. (2004). SCOPEC: a database of protein catalytic domains. Bioinformatics, Vol.20 Suppl 1, pp. i130-i136.  show abstract

Sheinerman, F.B., Al-Lazikani, B. & Honig, B. (2003). Sequence, structure and energetic determinants of phosphopeptide selectivity of SH2 domains. J mol biol, Vol.334 (4), pp. 823-841.  show abstract

Sheinerman, F.B., Al-Lazikani, B. & Honig, B. (2001). Predicting phosphopeptide selectivity of SH2 domains. Biophys j, Vol.80 (1), pp. 333A-333A.

Al-Lazikani, B., Jung, J., Xiang, Z. & Honig, B. (2001). Protein structure prediction. Curr opin chem biol, Vol.5 (1), pp. 51-56.  show abstract

Al-Lazikani, B., Sheinerman, F.B. & Honig, B. (2001). Combining multiple structure and sequence alignments to improve sequence detection and alignment: application to the SH2 domains of Janus kinases. Proc natl acad sci u s a, Vol.98 (26), pp. 14796-14801.  show abstract

Al-Lazikani, B., Lesk, A.M. & Chothia, C. (2000). Canonical structures for the hypervariable regions of T cell alphabeta receptors. J mol biol, Vol.295 (4), pp. 979-995.  show abstract

Al-Lazikani, B., Lesk, A.M. & Chothia, C. (1997). Standard conformations for the canonical structures of immunoglobulins. J mol biol, Vol.273 (4), pp. 927-948.  show abstract

Kinnersley, B., Sud, A., Coker, E.A., Tym, J.E., Di Micco, P., Al-Lazikani, B. & Houlston, R.S. Leveraging human genetics to guide cancer drug development. Jco clinical cancer informatics, .

Santos, R., Ursu, O., Gaulton, A., Bento, A.P., Donadi, R.S., Bologa, C.G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T.I., et al. A comprehensive map of molecular drug targets. Nat rev drug discov, Vol.16 (1), pp. 19-34.  show abstract

Yap, T.A., Smith, A.D., Ferraldeschi, R., Al-Lazikani, B., Workman, P. & de Bono, J.S. Drug discovery in advanced prostate cancer: translating biology into therapy. Nat rev drug discov, Vol.15 (10), pp. 699-718.  show abstract

Patel, M.N., Halling-Brown, M.D., Tym, J.E., Workman, P. & Al-Lazikani, B. Objective assessment of cancer genes for drug discovery. Nat rev drug discov, Vol.12 (1), pp. 35-50.  show abstract

Agüero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F.S., Campbell, R.K., Carmona, S., Carruthers, I.M., Chan, A.W., Chen, F., et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat rev drug discov, Vol.7 (11), pp. 900-907.  show abstract


Book Chapters

Al-Lazikani, B. (2014). Chemoinformatics for Bioinformaticians. Concise Encyclopaedia of Bioinformatics and Computational Biology. John Wiley & Sons, ISBN: 9780470978719.

Al-Lazikani, B., Gaulton, A., Paolini, G., Lanfear, J., Overington, J. & Hopkins, A. (2008). The Molecular Basis of Druggability. In Schreiber, S. (Ed.), Chemical Biology: From Small Molecules to Systems Biology and Drug Design.

Al-Lazikani, B., Gaulton, A., Paolini, G., Lanfear, J., Overington, J. & Hopkins, A. (2007). The Molecular Basis of Predicting Druggability. In Lengauer, T. (Ed.), Bioinformatics: molecular sequences and structures ; Vol 3, the holy grail : molecular function. (p. 1732). ISBN: 9783527312788.

Al-Lazikani, B., Chothia, C., Lesk, A., Morea, V., Rustici, M. & Tramontano, A. (1999). Immunoglobulin Structure. In Creighton, T.E. (Ed.), Encyclopedia of molecular biology. (p. 2856). Wiley-Interscience, ISBN: 9780471153023.


Conferences

Razaz, P., Workman, P. & Al-Lazikani, B. (2014). The druggable proteome: Identifying novel target families for cancer, CANCER RESEARCH, Vol.74 (19).

Howes, J., Lu, B.-., Powers, M., Mitsopoulos, C., Al-Lazikani, B., Linardopoulos, S., Clarke, P. & Workman, P. (2014). RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with HSP90 inhibition, CANCER RESEARCH, Vol.74 (19).

Steinbeck, C., Al-Lazikani, B., Hermjakob, H., Overington, J. & Thornton, J. (2009). New open drug activity data at EBI, Presented at 4th German Conference on Chemoinformatics, Goslar, GERMANY. CHEMISTRY CENTRAL JOURNAL, Vol.3,

Chan, A.W., Al-Lazikani, B., Carruthers, I., Cox, R., Dann, S., Davies, M., Michalovich, D. & Overington, J. (2005). GPCR knowledgebase - from sequences to ligands., Presented at 229th National Meeting of the American-Chemical-Society, San Diego, CA. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, Vol.229, p.U613.

Cox, R., Chan, A.W., Al-Lazikani, B., Michalovich, D. & Overington, L.P. (2005). Chemogenomic assessment of SAR data from learned journals, Presented at 230th National Meeting of the American-Chemical-Society, Washington, DC. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, Vol.230, p.U1035.

Al-Lazikani, B., Marks, D.J. & Segal, A.W. (2004). The structure of CARD15 and the molecular mechanisms of mutations associated with Crohn's disease, Presented at Digestive Disease Week/105th Annual Meeting of the American-Gastroenterological-Association, New Orleans, LA. GASTROENTEROLOGY, Vol.126 (4), p.A570.

Marks, D.J., Harbord, M., Al-Lazikani, B., Joshi, M., Bloom, S. & Segal, A.W. (2004). Failure of the acute inflammatory response in Crohn's disease: The influence of CARD15, Presented at Digestive Disease Week/105th Annual Meeting of the American-Gastroenterological-Association, New Orleans, LA. GASTROENTEROLOGY, Vol.126 (4), p.A151.

Marks, D.J., Harbord, M., Al-Lazikani, B., Joshi, M., Bloom, S. & Segal, A.W. (2004). Characterisation of the defect in acute inflammation in Crohn's disease and the influence of CARD15, Presented at Annual Meeting of the British-Society-of-Gastroenterology, Glasgow, SCOTLAND. GUT, Vol.53, pp.A103-A104.

In this section

Professional activities Publications Resources

Division of Cancer Therapeutics

The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments and biomarkers.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.